Taken together, these data described above suggest that anti‐IL‐17A and anti‐IL‐23 antibodies, if administered to patients with AD, interfere with neutrophil infiltration into AD brain and inhibit AD progression. This evidence concerns the gene IL17A and Alzheimer disease.